🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🚨Hot off the press! It was a true pleasure working with Zeynep Zengin and oncology luminaries Sumanta K. Pal, MD, FASCO and Petros Grivas on this commentary discussing chemoimmunotherapy in UC in the light of the results of KEYNOTE-361. City of Hope Department of Medical Oncology doi.org/10.1016/S1470-…

Just in The Lancet Oncology! Role of chemoimmunotherapy in urothelial carcinoma. Should we use concurrent or sequential therapy? Pleasure to work with Sumanta K. Pal, MD, FASCO, Petros Grivas, and Luis A. Meza on this commentary! 🔗thelancet.com/journals/lanon…

Outstanding educational session at #IKCS2021. Tour de force by Sumanta K. Pal, MD, FASCO, Dr. Nizar Tannir, and Tian Zhang, MD, MHS on the existing treatment options for mRCC and insightful comments on ongoing clinical trials in the space.

Such a great pleasure to meet and learn #RCC management from Sumanta K. Pal, MD, FASCO Tian Zhang, MD, MHS Dr. #NizarTannir in person again! Thanks to #IKCS2021 & PeerView 🙏 👉Attaching a few of their many important slides here for #MedTwitter #OncTwitter community Genitourinary Cancer Research Team @CityofHope

Low-cost, AmDTx mobile-app based intervention was acceptable & effective at addressing #FCR among pts w mRCC after only 2️⃣ wks Thank you Kure It 4 your support Thanks to my mentors Sumanta K. Pal, MD, FASCO Dr. Linda E. Carlson 🇨🇦 🇨🇦 Come to see our poster ASCO #GU22 meetings.asco.org/abstracts-pres…

🥁Check out these two posters presented by Jasnoor Malhotra incoming MS1 &🌟fellow of Sumanta K. Pal, MD, FASCO! ASCO #GU22 👏Congrats on your efforts in understanding patients' perspectives on #Immunotherapy #GenomicProfiling in #mRCC with senior author Cristiane D Bergerot!! OncoAlert UroToday.com

🥁 Check out Conquer Cancer, the ASCO Foundation winner #MeritAward poster of Luis A. Meza looking at the differentially abundant microbial species between pts with and without Gr3/4 AEs with nivo/ipi +/- CBM588 ASCO #GU22 Sumanta K. Pal, MD, FASCO Paulo G Bergerot Zeynep Zengin Tanya Dorff Genitourinary Cancer Research Team @CityofHope

🥁Thrilled to announce that our paper is out Nature Medicine! We looked at the impact of nivolumab/ipilimumab +/- #CBM588 a bifidogenic live bacterial product, on gut #Microbiome, serum cytokines & clinical outcomes in #mRCC 🙏🙏Sumanta K. Pal, MD, FASCO Luis A. Meza Paulo G Bergerot et al. 1/n🧵

Terrific group. Glad to see Jasnoor Malhotra & Zeynep Zengin from City of Hope getting guidance from visionary leaders in #kidneycancer like Turajlic Lab @ The Crick Laurence Albiges & so many others in this pic!

When's the last time you saw a fellow deliver a plenary session? Thrilled to see that Zeynep Zengin City of Hope will be giving remarks after legends Turajlic Lab @ The Crick & Grant Stewart. Major thx to #EAU22 organizers for giving opportunities to a diverse group of speakers!

What a force Zeynep Zengin is! So proud of her for delivering such a fantastic talk about the role of liquid biopsies in guiding treatment selection in RCC. Learning from the best, of course! Sumanta K. Pal, MD, FASCO #EAU22 #RCC

There’s so much waste in the OR it’s scary: syringes, drapes, disposables, a med student’s time when you don’t involve them.